RAPS Releases New Edition of Essential US Regulatory Affairs Reference Book
The Regulatory Affairs Professionals Society (RAPS) has published the updated, eighth edition of its essential regulatory reference book, Fundamentals of US Regulatory Affairs. The book provides extensive information on current regulatory requirements from FDA, and other state and federal agencies.
Fundamentals of US Regulatory Affairs, Eighth Edition includes updated regulatory information pertaining to pharmaceuticals, medical devices, biologics and other healthcare products intended for the US market. New content for this edition includes coverage of the Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012, and new chapters on pharmacovigilance, medical foods, crisis management, health technology assessment, and companion diagnostics. A chapter on Prescription Drug Product Submissions was revised by reviewers from FDA’s Center for Drug Evaluation and Research, and is publicly available online.
“This book is an outstanding overview of the drug, biologic and device regulatory pathways and requirements. It is thorough and clearly written,” said Edward Tabor, MD, vice president, regulatory affairs North America, Fresenius Kabi, and a member of RAPS’ board of directors. “Not only is it useful for anyone who wants to learn about the regulatory process; it also provides a ready reference for experienced regulatory professionals.”
In addition to being useful to professionals new to US regulatory affairs or as handy reference, many professionals preparing for the US Regulatory Affairs Certification (RAC) exam cite Fundamentals as an indispensable RAC study tool. It also has been used as a training resource at many healthcare organizations and is a mandatory text for university-level courses.
Fundamentals of US Regulatory Affairs, Eighth Edition is available both in print and as an e-book for $249.95 with free shipping for RAPS members or $309.95, plus shipping, for nonmembers.
Related News
-
News PSCI Welcomes Delpharm, Samsung Biologics, and Suven as First Supplier Partners
The pharmaceutical industry continues to evolve with an increasing focus on responsible sourcing, sustainability, and collaboration across the supply chain. Under a new model to recognise suppliers within the pharmaceutical and healthcare industry that... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News Eisai Alzheimer’s drug authorised in UK but still faces obstacles
In partnership with BioArctic AB, pharmaceutical company Eisai has been granted Marketing Authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA) for its Alzheimer’s disease drug product Leqembi. -
News Eli Lilly's weight loss drugs removed from the FDA's shortage list
The US FDA have recently updated their drug shortage list. The recently released list shows that all dosage forms of Eli Lilly's weight-loss drug Zepbound and their diabetes drug Mounjaro are now available. -
News Global advancements in the diagnosis and treatment of rare diseases: Rare Disease Day 2024
Rare Diseases Day is celebrated on the 29th February 2024 and represents the plight of rare disease patients to gain diagnosis and access to suitable treatment. -
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance